MEMORANDUM FOR SGVT
ATTN: CAPT AUSTIN PETERS

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

1. Your paper, entitled *Catheter Directed Therapy for Massive/Submassive Pulmonary Embolism* presented at Society of Interventional Radiology (SIR), Vancouver British Columbia Canada 2-5 April 2016 with MDWI 41-108, and has been assigned local file #16064.

2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.

3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are 59 MDW staff member, we can forward your request for funds to the designated wing POC.

4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC
Director, Clinical Investigations & Research Support

---

*Linda Steel-Goodwin*
PROCESSING OF PROFESSIONAL MEDICAL RESEARCH PUBLICATIONS/PRESENTATIONS

TO:
Clinical Research Division/SGVU
(59 MDW/SGVU)

FROM:
Author's Name, Rank, Grade, Office Symbol
PETERS, AUSTIN, CAPT, O-3, SGVT

PROTOCOL NUMBER:
N/A

PROTOCOL TITLE: [NOTE: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.]
N/A

1. TITLE OF MATERIAL TO BE PUBLISHED OR PRESENTED
Catheter directed therapy for massive/submassive pulmonary embolism

2. FUNDING RECEIVED FOR THIS STUDY? ☑ YES ☑ NO
FUNDING SOURCE:

3. IS THIS MATERIAL CLASSIFIED? ☑ YES ☑ NO

4. IS THIS MATERIAL SUBJECT TO ANY LEGAL RESTRICTIONS FOR PUBLICATION OR PRESENTATION THROUGH A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA), MATERIAL TRANSFER AGREEMENT (MTA), INTELLECTUAL PROPERTY RIGHTS AGREEMENT ETC.? ☑ YES ☑ NO
NOTE: If the answer is "YES" then attach a copy to the Agreement to the Publications/Presentations Request Form.

5. MATERIAL IS FOR (Check appropriate box or boxes for approval with this request.)
(ATTACH COPY OF MATERIAL TO BE PUBLISHED/PRESENTED)

☐ DOMESTIC RELEASE ☑ FOREIGN RELEASE

☐ PUBLICATION/JOURNAL (List intended publication/journal)

☐ PUBLICATION ABSTRACT (List intended journal)

☒ POSTER (To be demonstrated at meeting/Name of Meeting, City, State, and Date of Meeting)
Society of Interventional Radiology (SIR), Vancouver British Columbia Canada 2-5 April 2016

☐ PLATFORM PRESENTATION (At civilian institutions/Name of Meeting, State, Date of Meeting)

☐ OTHER (Describe: Name of Meeting, City, State, and Date of Meeting)

6. WHAT IS THE EXPECTED DATE YOUR PRESENTATION/PUBLICATION WILL BE SUBMITTED TO THE DEFENSE TECHNICAL INFORMATION CENTER (DTIC)?

POINT OF CONTACT

7. WHO IS THE PRIMARY 59 MDW POINT OF CONTACT? (Last, First, M.I.) (Include email)
PETERS, Austin J. austin.j.peters5.mil@mail.mil
DUTY PHONE/PAGER No.
210-916-3808/513-1718

AUTHORSHIP AND CO-AUTHOR(S) (List in the order they will appear in the manuscript)

<table>
<thead>
<tr>
<th>LAST NAME, FIRST NAME AND M.I.</th>
<th>GRADE/RANK</th>
<th>SQUADRON/GROUP/OFFICE SYM</th>
<th>INSTITUTION (If not 59 MDW)</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Primary/Corresponding author</td>
<td>O-3/Capt</td>
<td>959 CSPS/SGVT</td>
<td></td>
</tr>
<tr>
<td>b.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>d.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>e.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>f.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>g.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

I CERTIFY ANY HUMAN OR ANIMAL RESEARCH RELATED STUDIES WERE APPROVED AND PERFORMED IN STRICT ACCORDANCE WITH 32 CFR 219, AFMAN 46-401, IP AND 59 MDW 41-108. I HAVE READ THE FINAL VERSION OF THE ATTACHED MATERIAL AND CERTIFY THAT IT IS AN ACCURATE MANUSCRIPT FOR PUBLICATION AND/OR PRESENTATION.

AUTHOR'S PRINTED NAME/RANK/GRADE
Austin J. Peters, Capt, O-3

AUTHOR'S SIGNATURE
PETERS.AUSTIN.J.14038000674

APPROVING AUTHORITY'S PRINTED NAME, RANK, TITLE
Carlson, Christian, LTC, Residency Program Director

APPROVING AUTHORITY'S SIGNATURE
CARLSON.CHRISTIAN.LACELLE.11

DATE
Jan 8, 2016

59 MDW Form 3039 (DATE)
Supersedes 59 MDW Form 3039. 20131018
Page 2 of 3
TO: Clinical Research Division  
(59 MDW/SGVU)  
(Contact 292-7141 for email instructions)

1. DATE RECEIVED  
11 Jan 2016

2. ASSIGNED PROCESSING REQUEST FILE NUMBER  
16064

3. DATE REVIEWED  
13 Jan 2016

4. DATE FORWARD TO PA

5. AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHANGES  
☑ YES If yes give date: 13 Jan 2016  
☐ N/A

6. COMMENTS  
☑ APPROVED  
☐ DISAPPROVED

The article is approved.

PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER  
Rocky Calcote, PhD  
Clinical Research Administrator

DATE  
2nd INDOREMENT (PA Use Only)

TO: 59 MDW OFFICE OF PUBLIC AFFAIRS  
(PA)

1. DATE RECEIVED  
Jan 20, 2016

2. DATE FORWARD TO 59 MDW/SGVU  
Feb 18, 2016

6. COMMENTS  
☑ APPROVED (In compliance with security and policy review directives.)  
☐ DISAPPROVED

Content approved - needs review by OSI for foreign release.

PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER  
Christopher Carwile, TSgt/E-6, NCOIC, PA

DATE  
Feb 18, 2016

SIGNATURE OF REVIEWER  
CARWILE.CHRISTOPHER.S  
TEWART.1280477229

3rd INDOREMENT (SGVU Use Only)

TO: 59 MDW/SGVU

1. DATE RECEIVED

2. SENIOR AUTHOR NOTIFIED BY PHONE OF APPROVAL OR DISAPPROVAL:  
☐ YES  ☐ NO  ☐ Could not be reached  ☐ Left message

3. DATE WRITTEN NOTICE OF APPROVAL AND CLEARANCE MAILED TO AUTHOR:

4. COMMENTS  
☐ APPROVED  
☐ DISAPPROVED

PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER  
SIGNATURE OF REVIEWER  
DATE

59 MDW Form 3039 (DATE)  
Supersedes 59 MDW Form 3039, 20131018  
Page 3 of 3
From: Katie Tobin <ktobin@sirweb.org>
Sent: Friday, November 20, 2015 3:54 PM
To: Peters, Austin
Subject: SIR2016 Abstract Notification

Dear Austin Peters:

I am pleased to inform you that your abstract has been accepted for inclusion in the scientific program at the 2016 SIR 41st Annual Scientific Meeting in Vancouver, BC.

To confirm acceptance, please log into speaker sign-in < Caution-http://www.sirmeeting.org/index.cfm?do=cus.signInCustomer&cb=1022 > with your SIR username and password and view your invitation in your ready room. Please review the following presentation details and confirm acceptance at your earliest opportunity and no later than Tuesday, December 1st.

Abstract Title: Catheter directed therapy for massive and submassive pulmonary embolism: Level of evidence in the current literature.

Original abstract number: 1521
Final abstract number: 602

Presenting author: Austin Peters
Poster Hall location: Ballroom D-Level 1
Poster board size: Four feet (4') high by four feet (4') wide; the entire poster board area does not have to be utilized.

A Poster Reception will take place Tuesday, April 5, from 6:00 to 7:00 pm. One author should be present at that time to represent the work and answer questions. No formal presentation is required.

All poster presenters are required to register for the meeting; online registration is available at Caution-www.SIRmeeting.org < Caution-https://sir2015.abstractcentral.com/s1agxt/com.scholarone.s1agxt.s1agxt/s1agxt/Caution-www.SIRmeeting.org > . The early bird registration deadline is January 29th. For questions regarding your presentation or other annual scientific meeting information, please contact Katie Tobin at ktobin@SIRweb.org or call (703) 691-1805 ext. 561.

Your abstract will be published in the Journal of Vascular and Interventional Radiology (JVIR) March 2016 Supplement and will be a citable reference.

Please visit Caution-www.SIRmeeting.org < Caution-http://www.sirmeeting.org/index.cfm?do=cnt.page&pg=1032 > for details about the publication of the complete manuscript in JVIR.

Congratulations on your successful abstract submission. I look forward to seeing you in Vancouver!

Sincerely,

funaki, Brian copy.jpg

Brian Funaki, MD, FSIR

Chair, 2016 Scientific Program

Society of Interventional Radiology

Caution-www.SIRmeeting.org

P: (703) 691-1805
Catheter directed therapy for massive/submassive pulmonary embolism: Level of evidence in the current literature.

To critically examine the levels of evidence in the current literature for catheter directed therapy (CDT) of massive and submassive pulmonary embolism (PE) as well as provide suggestions for future research design.

Modern healthcare has developed interventions utilizing CDT for obstructive ischemia to the heart and brain. Yet acceptance of this approach to similar pathology in the lungs is still only recently developing in major medical centers and lacks widespread acceptance despite multiple published studies suggesting improved outcomes with CDT for massive and submassive PE. Excellent reviews exist regarding the general diagnosis and therapeutic options for PE, but there is a need for a compiled analysis on the quality of the present literature to provide guidance for future research design.

We examine the study designs and outcomes of several landmark studies of CDT for massive and submassive PE including the most recent ULTIMA and SEATTLE II trials. We describe the strengths and weaknesses of current literature specifically examining the patient populations, inclusion/exclusion parameters, standardization of measurements/technique, and study design. While the guidelines of various physician organizations involved in PE management are derived from level-one evidence of randomized controlled trials (RCTs), there is a paucity of RCT in the CDT literature.

The safety and efficacy of CDT for patients suffering PE has been well documented with the most documented methods being pigtail fragmentation and low dose intra-arterial thrombolysis. However, while previous trials have demonstrated promising results of CDT for massive and submassive PE, the level of evidence regarding patient outcomes has rarely been that which is required to cause a paradigm shift in patient intervention. As such, further RCTs or large prospective trials designed to examine the morbidity and mortality benefit of CDT with highly specific, objective, and reproducible parameters as described in detail in this paper are needed.

"The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense, or its components."